Former VP at Oncocyte Corp
- Molecular diagnostics market trends and developments, highlighting Oncocyte (NASDAQ: OCX)
- Product assessment – DetermaRx, DetermaIO, DetermaTx and DetermaCNI
- Commercialisation capabilities for Oncocyte’s diagnostics products, potential supply chain disruptions and third-party reimbursement dynamics
- Growth expectations and post-coronavirus outlook
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.